Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | AGER | Q15109 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8004518 | 0.80 | SLC6A9 (0.44) | SLC6A9SLC6A4KCNH2HSD11B1AGER | |
| SCHEMBL10722512 | 0.75 | HSD11B1 (0.56) | SLC6A9SLC6A4KCNH2HSD11B1AGER | |
| SCHEMBL8004431 | 0.74 | SLC6A4 (0.45) | SLC6A9SLC6A4KCNH2HSD11B1SLC6A5 | |
| SCHEMBL10724251 | 0.73 | SLC6A4 (0.56) | SLC6A9SLC6A4KCNH2HSD11B1AGER | |
| SCHEMBL13911269 | 0.72 | AGER (0.56) | SLC6A4KCNH2HSD11B1AGERMTNR1A | |
| SCHEMBL12139122 | 0.71 | SLC6A4 (0.43) | SLC6A9SLC6A4KCNH2HSD11B1AGER | |
| SCHEMBL23384719 | 0.71 | — | — | |
| SCHEMBL20646737 | 0.71 | — | — | |
| SCHEMBL9001743 | 0.71 | HSD11B1 (0.52) | SLC6A9SLC6A4KCNH2HSD11B1AGER | |
| SCHEMBL7604434 | 0.70 | NSD2 (0.54) | NSD2SLC6A9SLC6A4KCNH2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426607-B2 | Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426607-B2 | Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| WO-2009092566-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | PSEN1, AADAT, PSEN2 | NSD2 730/4885SLC6A9 2801/4885SLC6A4 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.